Last reviewed · How we verify
NCT05967767
Repeated Sprint Training in Normobaric Hypoxia
NA trial testing Normobaric Hypoxia Exposure in Hypoxia in 24 participants. Completed in 19 December 2022.
25 November 2022
Quick facts
| Lead sponsor | Ankara University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 1 November 2022 |
| Primary completion | 25 November 2022 |
| Estimated completion | 19 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Normobaric Hypoxia Exposure
- Normobaric Normoxia Exposure
Conditions studied
- Hypoxia — all drugs for Hypoxia →
Sponsor
Ankara University
Who can join
Adults 18 to 22, male only, with Hypoxia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the current study was to examine the effects of 3-session repeated sprint training performed in a normobaric hypoxic condition with 48-hour rest intervals on sprint performance indices, arterial oxygen saturation (SpO2) and rating of perceived exertion (RPE) scores. Twenty-four moderately-trained males participated in this study voluntarily basis. This study was conducted on single-blind placebo-controlled design. Participants were divided into three groups as follows; normobaric hypoxia (3420 m; HYP), normobaric normoxia (162 m; PLA) and control group (CON). HYP and PLA groups subjected to 3 repeated sprint training session (4 set x 5 x 5 s sprints with 30 s recovery and 5 min rest between the sets) in normobaric hypoxia or normoxia condition. Pre- and pos-test were conducted 72 hours before and after the training intervention period. All the training and testing sessions performed in cycle ergometer. There were no detected significant time and condition interaction in the variables; relative peak power output (PPO), mean power output (MPO), percentage of sprint decrement score (Sdec%) and RPE observed in the scope of pre- and post-test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05967767
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypoxia
Currently open trials in the same condition.
- NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
- NCT07287293 — Endotracheal Tube Suctioning Versus No Suctioning During Emergence From General Anesthesia · NA · recruiting
- NCT07389083 — The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Broncho · NA · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
- NCT07408388 — Pulse Oximeter Accuracy During Stable Hypoxia Plateaus · active not recruiting
Other Ankara University trials
Trials by the same sponsor.
- NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
- NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
- NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
- NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
- NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05967767 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara University
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967767.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing